Qingxia Fan

机构：First Affiliated Hospital of Zhengzhou University · ORCID：0009-0007-2892-7237

发表论文 173 篇 · 总被引 5329 次 · h-index 37

代表论文

• Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) (2022 · Nature Communications · 被引 151)
• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · ˜The œLancet. Gastroenterology & hepatology · 被引 88)
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 71)
• SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). (2024 · Journal of Clinical Oncology · 被引 31)
• LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (2023 · Annals of Oncology · 被引 31)
• Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)